Redmile Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Redmile Group’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-318,082	Closed	-$216K	–	79
2023 Q1	$216K	Sell	318,082 -1,265,076	-80%	-$1.61M	0.01%	76
2022 Q4	$2.61M	Hold	1,583,158	–	–	0.11%	59
2022 Q3	$7.33M	Sell	1,583,158 -152,958	-9%	-$899K	0.28%	54
2022 Q2	$8.79M	Sell	1,736,116 -678,316	-28%	-$4.94M	0.34%	52
2022 Q1	$17.2M	Sell	2,414,432 -85,568	-3%	-$577K	0.54%	46
2021 Q4	$24.4M	Buy	+2,500,000	New	+$22.2M	0.55%	43

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group's STLN Position: Q2 2023 in Review

Redmile Group sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2023, closing a stake of 318,082 shares — an estimated $216K sold.

Redmile Group first reported a position in STLN in Q4 2021 and held it in 6 quarters. The position peaked at $24.4M in Q4 2021. 38 funds tracked by Wall St. Rank hold STLN as of Q2 2023.

Redmile Group reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Redmile Group sold 318,082 Starling Oncology Institute, Inc. Common Stock shares in Q2 2023, an estimated $216K.
Redmile Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Redmile Group's Starling Oncology Institute, Inc. Common Stock position peaked at $24.4M in Q4 2021.
38 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2023.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.